公开(公告)号：EP3689875A1

公开(公告)日：2020-08-05

申请号：EP18860160.3

申请日：2018-08-29

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Suzhou Suplead Life Sciences Co., Ltd.

发明人： ZHOU, Bing ,  LUO, Cheng ,  YANG, Yaxi ,  ZHANG, Yuanyuan ,  DU, Daohai ,  JIANG, Hualiang ,  QIAO, Gang ,  WANG, Xinjun

IPC分类号： C07D487/04 ,  A61P35/00 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61P35/02 ,  A61P11/00

摘要： The present invention provides a compound represented by formula I, pharmaceutically acceptable salts, enantiomers, diastereomers or racemates thereof, the preparation method thereof, the pharmaceutical composition comprising the same, and the use thereof in the preparation of a medicament for treating a disease or condition mediated by EED and/or PRC2. The compound of the present invention can be used treating PRC2-mediated diseases or conditions.

公开(公告)号：EP3741758A1

公开(公告)日：2020-11-25

申请号：EP19740997.2

申请日：2019-01-11

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Suzhou Suplead Life Sciences Co., Ltd.

发明人： ZHOU, Bing ,  LUO, Cheng ,  LI, Zizhou ,  YANG, Yaxi ,  CHEN, Shijie ,  DING, Hong ,  JIANG, Hualiang ,  QIAO, Gang ,  WANG, Xinjun ,  XIAO, Senhao

IPC分类号： C07D487/04 ,  A61K31/53 ,  A61P35/00

摘要： The present invention relates to a bromodomain inhibitor. Provided are a compound represented by general formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, racemate, polymorph, solvate, or isotopically labeled compound (including deuterium substitution) thereof, a preparation method of the same, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof.